#United States #Atlanta #Artivion #NEXUS #Endospan

Artivion's Q1 2026 Financial Performance and Acquisition Announcement

Artivion, Inc., a prominent entity in the cardiac and vascular surgery domain focusing on aortic diseases, has reported its financial results for the first quarter ended March 31, 2026. The company continues to demonstrate solid growth trajectories, reflecting its strategic initiatives and product innovation.

Financial Highlights

During the first quarter of 2026, Artivion achieved a total revenue of $116.3 million, marking an 18% increase compared to the $99 million reported in the same period of the previous year. This increase is attributable to robust year-over-year performance across several product categories, particularly in stent grafts, On-X mechanical heart valves, and preservation services, which saw 21%, 20%, and 23% growth respectively. On a non-GAAP constant currency basis, the revenue growth stands at 12%.

The net income for the period was $1.4 million or $0.03 per fully diluted share, an improvement from the net loss of $0.5 million in the previous year. Non-GAAP metrics reveal a net income of $4.2 million or $0.08 per share, bolstering the company’s profitability narrative.

Adjusted EBITDA climbed 26% to reach $22.1 million, compared to $17.5 million in Q1 2025, affirming Artivion's effective operational strategies. Pat Mackin, the company’s Chairman and CEO, remarked on the strong enrollment numbers for the ARTIZEN clinical trial, alongside the unexpected U.S. FDA PMA approval for the NEXUS Aortic Arch System. This advancement dovetails into Artivion's ambition to lead in the aortic arch solutions market.

Strategic Acquisition of Endospan

A pivotal highlight of the quarter is Artivion's exercise of its option to acquire Endospan for an upfront amount of $135 million. This acquisition, which is anticipated to finalize in the second quarter of 2026, is expected to substantially enhance Artivion's market position. The NEXUS Aortic Arch System, which received FDA approval, will seamlessly integrate into Artivion's offerings, adding strategic advantage in addressing various aortic conditions, including chronic dissections.

Mr. Mackin explained, "The integration of Endospan and its NEXUS product not only expands our leading aortic arch portfolio but is also pivotal in positioning us as frontrunners in this vital segment. Furthermore, it broadens our pipeline with additional PMA programs."

As Artivion continues to strengthen its product line, expectations indicate that U.S. revenue from NEXUS product sales will commence in 2027 following strategic inventory builds and preparation for value analysis committee approvals.

Revised Financial Outlook

However, the company has adjusted its full-year revenue expectations for 2026. The new projections estimate total revenue between $480 million and $496 million, which reflects 7% to 11% growth year-over-year on an adjusted constant currency basis. The previous expectations ranged from $486 million to $504 million. Additionally, adjusted EBITDA projections have been revised downwards to anticipate growth between 12% and 20% for the year, re-estimating it to fall within $100 million to $107 million.

Despite recent performance indicating a dip in achieving constant currency expectations, management remains optimistic about recovery and reinforcing growth fundamentals.

Mr. Mackin concluded, "Our business demonstrates strong reordering behavior from AMDS accounts that have exceeded expectations, reinforcing our confidence in long-term adoption, while On-X continues to gain market share as the preferred aortic valve for patients under 65."

Conclusion

Artivion's Q1 2026 results reflect a significant momentum driven by strategic decisions and product innovations tailored to meet critical health needs. With the acquisition of Endospan and the expansion of its product line, the company is poised to further solidify its position within the aortic health market, paving the way for continued growth and innovation.